Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aryeh Fischer

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Therapeutic Advances in Respiratory Disease|October 17, 2024
Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United StatesYing Qiu, Julia Zhu, Pooja Chopra, et al.
The Journal of Rheumatology|June 20, 2006
Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosisAryeh Fischer, Frederick J Pfalzgraf, Carol A Feghali-Bostwick, et al.
Respiratory Medicine|May 18, 2010
Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung diseaseJeffrey J Swigris, Janelle Yorke, David B Sprunger, et al.
Journal of Scleroderma and Related Disorders|February 27, 2020
Review of local wound management for scleroderma-associated digital ulcersNicholas Lebedoff, Tracy M Frech, Victoria K Shanmugam, et al.
Respiratory Medicine|May 16, 2017
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung diseaseJake G Natalini, Jeff J Swigris, Julie Morisset, et al.
The Journal of Rheumatology|July 3, 2016
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS TrialDinesh Khanna, Carlo Albera, Aryeh Fischer, et al.
BMJ Open Respiratory Research|September 21, 2018
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Respiratory Research|March 19, 2022
LPA<sub>1</sub> antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosisBenjamin E Decato, Diana Julie Leeming, Jannie Marie Bülow Sand, et al.
Chest|July 15, 2006
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung diseaseJeffrey J Swigris, Amy L Olson, Aryeh Fischer, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 16, 2024
Circulating biomarker analyses in a longitudinal cohort of patients with IPFChristina Ebert, Alice M Walsh, Larisa Sereda, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Therapeutic Advances in Respiratory Disease|October 17, 2024
Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United StatesYing Qiu, Julia Zhu, Pooja Chopra, et al.
The Journal of Rheumatology|June 20, 2006
Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosisAryeh Fischer, Frederick J Pfalzgraf, Carol A Feghali-Bostwick, et al.
Respiratory Medicine|May 18, 2010
Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung diseaseJeffrey J Swigris, Janelle Yorke, David B Sprunger, et al.
Journal of Scleroderma and Related Disorders|February 27, 2020
Review of local wound management for scleroderma-associated digital ulcersNicholas Lebedoff, Tracy M Frech, Victoria K Shanmugam, et al.
Respiratory Medicine|May 16, 2017
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung diseaseJake G Natalini, Jeff J Swigris, Julie Morisset, et al.
The Journal of Rheumatology|July 3, 2016
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS TrialDinesh Khanna, Carlo Albera, Aryeh Fischer, et al.
BMJ Open Respiratory Research|September 21, 2018
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Respiratory Research|March 19, 2022
LPA<sub>1</sub> antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosisBenjamin E Decato, Diana Julie Leeming, Jannie Marie Bülow Sand, et al.
Chest|July 15, 2006
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung diseaseJeffrey J Swigris, Amy L Olson, Aryeh Fischer, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 16, 2024
Circulating biomarker analyses in a longitudinal cohort of patients with IPFChristina Ebert, Alice M Walsh, Larisa Sereda, et al.
Pageof 11